Dianthus Therapeutics, Inc. (DNTH) stock
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$86.98−2.57 (-2.87%)
Close on Nov 17, 2026Market cap $4.87BP/E –Yield 0.00%
Dianthus Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Dianthus Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $2.04M, down 67.3% year over year. For fiscal 2025 it was $2.04M, down 67.3% from the year before. The highest annual figure on record is $6.24M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04M | -67.3% |
| FY2024 | Dec 31, 2024 | $6.24M | +120.6% |
| FY2023 | Dec 31, 2023 | $2.83M | – |
| FY2019 | Dec 31, 2019 | $0 | – |
| FY2018 | Dec 31, 2018 | $0 | – |
| FY2017 | Dec 31, 2017 | $0 | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $284.00K | -78.6% |
| Q3 FY2025 | Sep 30, 2025 | $396.00K | -81.8% |
| Q2 FY2025 | Jun 30, 2025 | $193.00K | -89.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.16M | +33.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.33M | +190.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.17M | +135.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.86M | +58.8% |
| Q1 FY2024 | Mar 31, 2024 | $874.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $457.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $924.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $1.17M | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
See a number that looks wrong?